Payment overview · 2025
General Payments
$61.94
4 reported records · 3 companies
Healthcare provider profile · identity verified
Vincent Bryan Lococo, MD
Allopathic & Osteopathic Physicians|Family Medicine · SPRINGHILL, LA · NPI 1093745648
Verified facts
What the public records show
CMS Open Payments records show Vincent Bryan Lococo, MD received $61.94 in general payments during 2025 across 4 reported records.
Neurocrine BioSciences, Inc. accounted for 54.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 350 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $33.66 | 54.3% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $14.66 | 23.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.62 | 22.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $61.94 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $33.66 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 24 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
350 | 56 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 672 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 509 | 79 |
| Eliquis | Apixaban | 350 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 340 | 71 |
| Duloxetine Hcl | Duloxetine Hcl | 286 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 253 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 237 | 35 |
| Spironolactone | Spironolactone | 229 | 43 |
| Trazodone Hcl | Trazodone Hcl | 222 | 40 |
| Donepezil Hcl | Donepezil Hcl | 213 | 31 |
| Furosemide | Furosemide | 212 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 211 | 58 |
| Carvedilol | Carvedilol | 205 | 40 |
| Mirtazapine | Mirtazapine | 199 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 184 | 32 |
| Losartan Potassium | Losartan Potassium | 181 | 36 |
| Memantine Hcl | Memantine Hcl | 181 | 24 |
| Metformin Hcl Er | Metformin Hcl | 159 | 48 |
| Mounjaro | Tirzepatide | 158 | 30 |
| Sertraline Hcl | Sertraline Hcl | 157 | 47 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 156 | 48 |
| Potassium Chloride | Potassium Chloride | 147 | 35 |
| Jardiance | Empagliflozin | 140 | 23 |
| Famotidine | Famotidine | 130 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 128 | 29 |
| Finasteride | Finasteride | 126 | 17 |
| Levetiracetam | Levetiracetam | 122 | 12 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 117 | 12 |
| Omeprazole | Omeprazole | 115 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 114 | 41 |
| Divalproex Sodium | Divalproex Sodium | 112 | 11 |
| Kerendia | Finerenone | 112 | 11 |
| Sucralfate | Sucralfate | 111 | 15 |
| Gabapentin | Gabapentin | 104 | 34 |
| Pregabalin | Pregabalin | 104 | 26 |
| Amiodarone Hcl | Amiodarone Hcl | 102 | 14 |
| Metformin Hcl | Metformin Hcl | 101 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 29 |
| Aripiprazole | Aripiprazole | 97 | 17 |
| Entresto | Sacubitril/Valsartan | 91 | 17 |
| Lactulose | Lactulose | 90 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 90 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 20 |
| Alendronate Sodium | Alendronate Sodium | 84 | 15 |
| Lisinopril | Lisinopril | 82 | 28 |
| Tramadol Hcl | Tramadol Hcl | 82 | 31 |
| Risperidone | Risperidone | 78 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 76 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 69 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 63 | 20 |
| Topiramate | Topiramate | 63 | 12 |
| Bumetanide | Bumetanide | 57 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 55 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 54 | suppressed |
| Digoxin | Digoxin | 51 | suppressed |
| Myrbetriq | Mirabegron | 50 | 12 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 49 | 13 |
| Novolog Flexpen | Insulin Aspart | 49 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | suppressed |
| Alprazolam | Alprazolam | 47 | 16 |
| Fluconazole | Fluconazole | 47 | 28 |
| Buspirone Hcl | Buspirone Hcl | 46 | 11 |
| Prednisone | Prednisone | 43 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 40 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 39 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 39 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 37 | suppressed |
| Estradiol | Estradiol | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 11 |
| Acarbose | Acarbose | 34 | 13 |
| Latanoprost | Latanoprost | 32 | suppressed |
| Minoxidil | Minoxidil | 32 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | 24 |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Fentanyl | Fentanyl | 30 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 14 |
| Gemtesa | Vibegron | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 23 |
| Trulicity | Dulaglutide | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | 15 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 24 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 13 |
| Edurant | Rilpivirine Hcl | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Rivastigmine | Rivastigmine | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Allopurinol | Allopurinol | 22 | 12 |
| Erythromycin | Erythromycin Base | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | 13 |
| Promethazine Hcl | Promethazine Hcl | 22 | 17 |
| Tadalafil | Tadalafil | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Mesalamine | Mesalamine | 20 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Trimethoprim | Trimethoprim | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Simvastatin | Simvastatin | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Np Thyroid | Thyroid,pork | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Tivicay | Dolutegravir Sodium | 17 | suppressed |
| Budesonide Dr | Budesonide | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | 11 |
| Ozempic | Semaglutide | 16 | suppressed |
| Prilosec | Omeprazole Magnesium | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Baclofen | Baclofen | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Lumigan | Bimatoprost | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 15 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | 12 |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 14 | 11 |
| Acyclovir | Acyclovir | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Procrit | Epoetin Alfa | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $61.94 · 4 records | Neurocrine BioSciences, Inc. | ABRYSVO, AUSTEDO XR, COMIRNATY, INGREZZA, PREVNAR 20 | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error